$RVMD News

Revolution Medicines (NASDAQ:RVMD) Flashes Strong Technical Breakout Setup

Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $192.1

Revolution Medicines' New Drug Application For Daraxonrasib Receives FDA Acceptance For Review To Treat Metastatic Pancreatic Ductal Adenocarcinoma

Needham Maintains Buy on Revolution Medicines, Raises Price Target to $236

Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $235

European Medicines Agency's Human Medicines Committee Initiates Phased Review Of Revolution Medicines' Daraxonrasib To Treat Metastatic Pancreatic Cancer

HC Wainwright & Co. Reiterates Buy on Revolution Medicines, Maintains $195 Price Target

Mizuho Maintains Outperform on Revolution Medicines, Raises Price Target to $215

Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $181

Revolution Medicines Announces Zoldonrasib Showed Manageable Safety, Tolerability Profile In Two Phase 1/2 Clinical Studies; Objective Response Rate Stood At 82%, Disease Control Rate Was 96%

Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $210

Needham Maintains Buy on Revolution Medicines, Raises Price Target to $235

Revolution Medicines Begins Treating Patients In RASolute 305, Global, Randomized Phase 3 Clinical Trial Evaluating Zoldonrasib In Combination With Standard Of Care Chemotherapy As First Line Treatment In Patients With Metastatic RAS G12D PDAC

$1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today

Revolution Medicines: Strong Data, Big Market (Rating Upgrade)

Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $220

RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $182

HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $195

Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $195

Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs